Prescription Stimulant Medical and Nonmedical Use Among US Secondary School Students, 2005 to 2020

Abstract

ImportanceRecent information on the prevalence of prescription stimulant therapy for attention-deficit/hyperactivity disorder (ADHD) and nonmedical use of prescription stimulants (NUPS) at the school-level among US secondary school students is limited.ObjectiveTo investigate the school-level prevalence of and association between stimulant therapy for ADHD and NUPS among US secondary school students.Design, Setting, and ParticipantsThis cross-sectional study used survey data collected between 2005 and 2020 as part of the Monitoring the Future study (data collected annually via self-administered survey in schools from independent cohorts). Participants were from a nationally representative sample of 3284 US secondary schools. The mean (SD) response rates were 89.5% (1.3%) for 8th-grade students, 87.4% (1.1%) for 10th-grade students, and 81.5% (1.8%) for 12th-grade students. Statistical analysis was performed from July to September 2022.Main Outcome and MeasurePast-year NUPS.ResultsThe 3284 schools contained 231 141 US 8th-, 10th-, and 12th-grade students (111 864 [50.8%, weighted] female; 27 234 [11.8%, weighted] Black, 37 400 [16.2%, weighted] Hispanic, 122 661 [53.1%, weighted] White, 43 846 [19.0%, weighted] other race and ethnicity). Across US secondary schools, the past-year prevalence of NUPS ranged from 0% to more than 25%. The adjusted odds of an individual engaging in past-year NUPS were higher at secondary schools with higher proportions of students who reported stimulant therapy for ADHD, after controlling for other individual-level and school-level covariates. Students attending schools with the highest rates of prescription stimulant therapy for ADHD had approximately 36% increased odds of past-year NUPS compared with students attending schools with no medical use of prescription stimulants (adjusted odds ratio, 1.36; 95% CI, 1.20-1.55). Other significant school-level risk factors included schools in more recent cohorts (2015-2020), schools with higher proportions of parents with higher levels of education, schools located in non-Northeastern regions, schools located in suburban areas, schools with higher proportion of White students, and schools with medium levels of binge drinking.Conclusions and RelevanceIn this cross-sectional study of US secondary schools, the prevalence of past-year NUPS varied widely, highlighting the need for schools to assess their own students rather than relying solely on regional, state, or national results. The study offered new evidence of an association between a greater proportion of the student body that uses stimulant therapy and a greater risk for NUPS in schools. The association between greater school-level stimulant therapy for ADHD and other school-level risk factors suggests valuable targets for monitoring, risk-reduction strategies, and preventive efforts to reduce NUPS.

Chronic oral methylphenidate plus fluoxetine treatment in adolescent rats increases cocaine self-administration

“…Aside from its medicinal benefits, MP is often used illicitly among high school and college students to increase cognitive function or as a party drug [ 1 , 2 ]. Off-label use of MP is most common among 18- to 25-year-olds and recent data shows that as many as 25% of high school students engage in nonmedical use of prescription stimulants (NUPS) [ 3 ]. In fact, students that attended high schools with the greatest rates of psychostimulant therapy for ADHD had 36% increased odds of NUPS compared with students attending schools with the lowest rates [ 3 ].…”

“…Off-label use of MP is most common among 18- to 25-year-olds and recent data shows that as many as 25% of high school students engage in nonmedical use of prescription stimulants (NUPS) [ 3 ]. In fact, students that attended high schools with the greatest rates of psychostimulant therapy for ADHD had 36% increased odds of NUPS compared with students attending schools with the lowest rates [ 3 ]. ADHD is often associated with depression and anxiety.…”